Compliance · State rules

Office-use compounding in South Dakota

No authorising rule and no express prohibition; closed by the structure of the rules, as an inference

USPeptideRx EditorialLast reviewed: August 31, 2026

South Dakota never wrote an office-use rule and never wrote a prohibition either, so the answer here has to be read out of the structure rather than quoted from a holding — and this page labels it as the inference it is. Every route to a compounded preparation in South Dakota law is tethered to a named patient: the statutory definition of compounding runs through a prescription drug order, a prescription drug order is defined as an order for a specific patient, the rule listing what a valid prescription must contain makes the patient’s full legal name and address an element of it, and the surviving labelling rule requires the patient’s name on the container. The one South Dakota provision that uses the words "office use" is not a permission at all; it is a track-and-trace carve-out, and the definition next to it pointedly does not carry the same carve-out.

The governing rule

South Dakota’s office-use position is set by SDCL 36-11-2(4) and (21), with ARSD 20:51:05:15 and 20:51:05:22. The text below is quoted verbatim; everything outside a quote block is our summary of it, and the two are kept visually separate on purpose.

SDCL 36-11-2(4) — the statutory definition of compounding

"Compounding," the preparation, mixing, assembling, packaging, or labeling of a drug or drug device, as the result of a practitioner’s prescription drug order or an initiative based on the pharmacist, patient, and practitioner relationship in the course of professional practice, or for the purpose of or as an incident to research, teaching, or chemical analysis, and not for sale or dispensing. The term also includes the preparation of drug or drug devices in anticipation of prescription drug orders based on routine, regularly observed prescribing patterns;

SDCL 36-11-2(21) — what a prescription drug order is

"Prescription drug order," a written or oral order of a practitioner for a drug or drug device for a specific patient;

ARSD 20:51:05:22 — the five per cent distribution rule, and the purpose that gates it

Distribution of drugs to prescribers or pharmacies. A licensed pharmacy may distribute up to five percent of its controlled drugs and legend drugs to a prescriber licensed to prescribe, dispense, or distribute the drugs in the course of professional practice or to other licensed pharmacies, to meet temporary inventory shortages.

SDCL 36-11A-1.2 — "Transaction defined", showing where the office-use words actually sit (elision marked)

As used in this chapter, the term, transaction, means the transfer of product between trading partners in which a change of ownership occurs. The term does not include: … (7) The distribution of minimal quantities of product by a licensed retail pharmacy to a licensed practitioner for office use;

SDCL 36-11A-2 — "Distribution defined", whose exclusion list does not carry the same carve-out (elision marked)

As used in this chapter, the term, distribution, means the sale, purchase, trade, delivery, handling, storage, or receipt of a product. The term does not include: … (7) The transfer of drugs by a pharmacy to another pharmacy to alleviate a temporary shortage;

What the rule requires in practice

Each item carries a confidence level. Verbatim rule text is high confidence; a reading of how two provisions interact, or a source that could not be re-verified, is not.

This verdict is an inference, and we would rather say so than overstate itMedium confidence: South Dakota has written no rule authorising office use and no rule forbidding it by name. The closed reading rests on the statutory definition of compounding, the definition of a prescription drug order, the rule stating what a valid prescription must contain, and the surviving labelling rule — four provisions that all assume a named patient. That is a strong structural case. It is not a quotable holding, and anyone who presents it as one is overselling it.
The one "office use" provision in South Dakota law grants nothingHigh confidence: It sits inside the definition of a "transaction" in the state’s track-and-trace chapter, so its whole legal effect is that a qualifying shipment does not trigger transaction information, history and statement obligations. And the proof that this is the correct reading is next door: the section defining "distribution" has its own exclusion list, that list carves out pharmacy-to-pharmacy transfers to relieve a temporary shortage, and it does not carve out pharmacy-to-practitioner office use. The legislature took office use out of one definition and pointedly left it inside the other. Supplying a prescriber is distribution in South Dakota; it merely is not a transaction.
The five per cent rule is a real permission, and its gate is the purpose, not the numberHigh confidence: A licensed pharmacy may distribute up to five per cent of its controlled and legend drugs to a prescriber — but only "to meet temporary inventory shortages". The percentage is a ceiling on a channel that exists for a stated reason, and a standing office-supply arrangement is not a temporary inventory shortage. The rule also reaches legend drugs generally rather than compounded preparations specifically.
That rule acquired a paperwork regime in 2024 that had not existed for decadesHigh confidence: The distribution must be documented on invoices carrying the name, address and DEA number of both locations, the drug name, dosage form and strength, the quantity of each drug sold and the date of sale; sales of Schedule II drugs require a completed DEA form 222; and both locations must keep copies for two years. A 2025 amendment then changed "registered" to "licensed" in the same rule. Anyone working from a pre-2024 description of this rule is missing the entire record-keeping half of it.
South Dakota has three separate five per cent provisions and they do different thingsHigh confidence: One is the ceiling above. A second, in statute, runs the opposite way — it is a status threshold, and a pharmacy whose deliveries reach five per cent of its total gross sales becomes a pharmacy distributor with a licence, a bond and a designated representative to obtain. A third belongs to the practitioner rather than the pharmacy, and lets a registrant distribute up to five per cent of its own controlled substances to other registrants. They share a number and nothing else; treating them as one rule inverts at least one of them.
Two definitions of compounding are in force at once and they do not agreeHigh confidence: The statutory definition is tethered to a patient throughout. The board’s rule-level definition is a pure process test — a change in the form, composition or strength of any ingredient or any other attribute of a product — with no patient tether at all. A rule cannot expand a statute, so the statute governs; but the rule is the one a competitor will quote, and it is worth knowing which is which.
There is no compounded-preparation label rule, because it was repealedHigh confidence: The labelling rule in the compounding chapter was repealed effective 2 June 2024, in a sweep that repealed thirty consecutive rules and replaced them with a single incorporation of the USP chapters pinned to the 1 February 2024 edition. What survives is the general prescription-container labelling rule, and it requires the name of the patient.
Sterile and non-sterile are treated identicallyHigh confidence: The surviving incorporation applies USP chapters 795, 797, 800 and 825 to all sterile compounding, non-sterile compounding and repackaging together. There is no sterility split to work with, and a separate rule requires any compounding pharmacy to meet the physical, equipment and environmental requirements those chapters establish.
Last change, and a recent oneHigh confidence: Seventy-one sections of the pharmacy article were amended with effect from 16 August 2026. That sweep did not touch the compounding chapter or the five per cent distribution rule, both of which were last amended in 2024 and 2025. Any South Dakota brief written before mid-August 2026 should nonetheless be re-read, because the prescription-contents rule was among the sections it did amend.

South Dakota at a glance

South Dakota office-use compounding summary, reviewed 2026-08-31
Human office use	No authorising rule and no express prohibition; closed by structure, as an inference
Sterile preparations	No split — one incorporation covers sterile, non-sterile and repackaging alike
Quantity cap	Five per cent, gated on meeting temporary inventory shortages
Mandatory label legend	None — the compounding label rule was repealed; the survivor names the patient
Board reporting	Invoices with DEA numbers, retained two years by both parties
Last change	Article-wide amendments effective 16 August 2026
Governing rule	SDCL 36-11-2(4) and (21), with ARSD 20:51:05:15 and 20:51:05:22

Receiving 503B office stock in South Dakota

South Dakota uses the industry’s own vocabulary for the facility, prices the licence at its statutory ceiling and backs it with a felony. The trap for a reader is that the Board of Pharmacy sits inside the Department of Health, which makes it easy to miss that the two act in different capacities and that only one of them registers controlled substances.

Everything above this heading answers the supply question: may a state-licensed 503A pharmacy ship non-patient-specific stock? This section answers the other half. Registration with FDA under section 503B is a federal exemption from federal law and preempts no state licensing scheme, so it is never the whole answer on its own — a state credential is the norm rather than the exception, it is not always issued by the board of pharmacy, and in some states the category you would search for does not exist. What South Dakota asks for is set out below, including where we could not establish it.

What the 503B must hold to ship inHigh confidence: A board licence. The statute requires each wholesale distributor and outsourcing facility located inside or outside the state that provides services to outlets within it to be licensed annually, and the chapter defines an outsourcing facility by compliance with federal section 503(b) as of 1 January 2017 plus FDA registration and inspection. The annual fee is set by the board and capped by statute at $500, a bond of at least $100,000 or equivalent security is required, and a distributor shipping from more than one facility must license each one.Operating as an out-of-state wholesale drug distributor without the licence is a Class 6 felony — the sharpest sanction attached to this question anywhere on this site.
Does your practice need a permit?Medium confidence: The pharmacy chapter does not apply to a physician acting as a physician, or interfere with supplying drugs to that physician’s own patients. Read the limit as well as the exemption: it runs to "his patients", so it is an exemption for treating people, not a general licence-free zone for holding stock. The authority of nurse practitioners and physician assistants to procure and administer sits in their own practice acts rather than in the pharmacy act, and is beyond the scope of this page.
Administer vs dispenseHigh confidence: South Dakota’s answer runs through the prescription rather than through the act. A pharmacist may dispense only pursuant to a valid prescription, and the rule setting out what a valid prescription contains makes the patient’s full first and last legal name and address an element. That requirement bites at the point of supply, which is why the administer-versus-dispense distinction does less work here than in most states.
Scheduled (controlled) stockHigh confidence: South Dakota requires its own controlled-substance registration, and the registrar is the Department of Health rather than the Board of Pharmacy — a distinction easy to miss because the board is housed within that department. It reaches any person who prescribes, manufactures, distributes or dispenses, and a separate registration is required at each principal place of business or professional practice.

How to check a facility’s credential before you order is set out in how to place an office-use order.

The federal layer still applies

Federal law is a second, independent constraint — a state prohibition is not the only thing standing in the way. 21 U.S.C. § 353a conditions the federal compounding exemptions on a drug being compounded for an identified individual patient on receipt of a valid prescription order. A state rule cannot create a federal safe harbour, and several state rules say so in their own text. The separate federal pathway for non-patient-specific office stock is the 503B outsourcing facility — the differences are set out in 503A vs 503B.

For how South Dakota compares with the other states reviewed, see the state-by-state comparison.

What this page does not establish

The verdict on this page is a structural inference, not a quotation. South Dakota has written neither an authorising rule nor an express prohibition, and we would rather label the reasoning than dress it up as a holding. If you need certainty here, the Board is the place to get it.
The Board adopted a policy statement in September 2023 to set its expectations on the USP compounding standards, and its own newsletter says the statement is published on its website. We did not obtain the text of it. If a South Dakota position on office use has been stated anywhere, that document is the likeliest place, and this page does not account for it.
Whether the five per cent ceiling is measured in units or in dollars is not resolved. The rule does not say, and no guidance we read supplies an answer.
One practical warning if you go looking for South Dakota rule text yourself, because it will cost you an afternoon otherwise: the legislature’s own site answered five structurally different addresses — including two that look like data endpoints — with the same small application shell, a success status and no legal text at all, and it ignored an explicit request for data rather than a web page. This page is sourced to the Board’s consolidated publication instead, which carries the operative text.
We searched no case law, attorney-general opinions or declaratory rulings for this state, and search engines were unavailable when it was researched. Read nothing into that silence — it means we have not looked, not that nothing is there.

Sources

Primary sources, fetched directly from the issuing body. No secondary summaries.